These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 10685654

  • 1. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW.
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [Abstract] [Full Text] [Related]

  • 2. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 3. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs.
    Kilbourn RG, Cromeens DM, Chelly FD, Griffith OW.
    Crit Care Med; 1994 Nov 15; 22(11):1835-40. PubMed ID: 7956289
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Nov 15; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 5. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [Abstract] [Full Text] [Related]

  • 6. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB.
    Clin Cancer Res; 1998 May 15; 4(5):1203-13. PubMed ID: 9607578
    [Abstract] [Full Text] [Related]

  • 7. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension.
    Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ.
    Crit Care Med; 1995 Jun 15; 23(6):1018-24. PubMed ID: 7774211
    [Abstract] [Full Text] [Related]

  • 8. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL, Stadler WM, Vogelzang NJ.
    Urology; 1996 Feb 15; 47(2):194-7. PubMed ID: 8607232
    [Abstract] [Full Text] [Related]

  • 9. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US, White DE, Rosenberg SA.
    Cancer; 1998 Aug 15; 83(4):797-805. PubMed ID: 9708948
    [Abstract] [Full Text] [Related]

  • 10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 15; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 11. Overview of interleukin-2 inhalation therapy.
    Huland E, Heinzer H, Huland H, Yung R.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 15; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 13. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct 15; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 14. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S.
    Clin Cancer Res; 1997 Apr 15; 3(4):565-72. PubMed ID: 9815721
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [Abstract] [Full Text] [Related]

  • 16. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar 15; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 17. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
    Hank JA, Albertini M, Wesly OH, Schiller JH, Borchert A, Moore K, Bechhofer R, Storer B, Gan J, Gambacorti C.
    Clin Cancer Res; 1995 May 15; 1(5):481-91. PubMed ID: 9816007
    [Abstract] [Full Text] [Related]

  • 18. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
    Kilbourn RG, Owen-Schaub LB, Cromeens DM, Gross SS, Flaherty MJ, Santee SM, Alak AM, Griffith OW.
    J Appl Physiol (1985); 1994 Mar 15; 76(3):1130-7. PubMed ID: 8005855
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, Coudert B, Négrier S, Groupe Français d'Immunothérapie.
    Cancer; 2002 Dec 01; 95(11):2324-30. PubMed ID: 12436438
    [Abstract] [Full Text] [Related]

  • 20. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb 01; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.